Tafenoquine for preventing relapse in people with Plasmodium vivax malaria
S Rajapakse, C Rodrigo… - Cochrane database of …, 2015 - cochranelibrary.com
Cochrane database of systematic reviews, 2015•cochranelibrary.com
Background Plasmodium vivax malaria is widespread, and the persistent liver stage causes
relapse of the disease which contributes to continued P. vivax transmission. Primaquine is
currently the only drug that cures the parasite liver stage, but requires 14 days to be effective
and can cause haemolysis in people with glucose‐6‐phosphate dehydrogenase (G6PD)
deficiency. In addition, there is some evidence of parasite resistance to the drug.
Tafenoquine is a new alternative with a longer half‐life. Objectives
relapse of the disease which contributes to continued P. vivax transmission. Primaquine is
currently the only drug that cures the parasite liver stage, but requires 14 days to be effective
and can cause haemolysis in people with glucose‐6‐phosphate dehydrogenase (G6PD)
deficiency. In addition, there is some evidence of parasite resistance to the drug.
Tafenoquine is a new alternative with a longer half‐life. Objectives
Background
Plasmodium vivax malaria is widespread, and the persistent liver stage causes relapse of the disease which contributes to continued P. vivax transmission. Primaquine is currently the only drug that cures the parasite liver stage, but requires 14 days to be effective and can cause haemolysis in people with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency. In addition, there is some evidence of parasite resistance to the drug. Tafenoquine is a new alternative with a longer half‐life.
Objectives
cochranelibrary.com